You defend a product's price and coverage with evidence. ClinicaLister puts real US pricing and Medicare spend — acquisition cost, ASP, Part D, transparency payments, shortages — right next to the drug and its trials, so the multi-portal CMS and FDA hunt that used to fill your week is already assembled and sourced.
The highest-leverage things ClinicaLister does for a market access / heor.
Every recurring activity, mapped to what ClinicaLister does — on which surface (the App, the MCP graph, or both), the time it saves, and how confident that claim is.
| Activity | What ClinicaLister does | Surface | Time saved | Confidence |
|---|---|---|---|---|
| Acquisition-cost benchmarking (NADAC) | Per-unit acquisition cost with the brand-versus-generic differential and drug class, in one benchmark table. | MCP | hours of CMS-file wrangling → one table | High |
| ASP for Part B / infused products | The CMS average sales price per drug — the defensible anchor for infused and Part B products. | MCP | manual CMS ASP lookup eliminated | High |
| Medicare / Part D spend + utilization | Medicare Part D spend and utilization per drug, summarised into a single spending brief. | MCP | a multi-tab CMS dashboard → a single brief | High |
| YoY spend trend & price inflection | Year-over-year spend trajectory with growth ranking and per-unit price-inflection detection. | MCP | trend deck from raw files → auto-ranked | High |
| Open Payments / KOL & compliance | Manufacturer-to-HCP transparency payments per drug, structured into a compliance and KOL-engagement report. | MCP | Open Payments portal scraping → structured report | High |
| Shortage supply-chain risk | Current FDA shortage status per drug, turned into a risk-scored supply view. | MCP | ad-hoc FDA checks → a risk-scored view | High |
| Observed generic / biosimilar erosion | See which generics and biosimilars are already approved on a moiety and size the incumbent with Part D spend and ASP. This is observed erosion — NOT a forecast: exclusivity end-dates are on 1.8% of records, so entry-window timing is not available. | Both | observed erosion, sized — no timing | Medium |
| NDC-level product mapping | Package, label, and manufacturer resolved down to the NDC, without the manual directory joins. | MCP | manual NDC directory joins removed | High |
| Label ↔ priced product tie-out | Official FDA labels tied to the priced product, matching indication and formulation to the right NDC. | Both | indication / formulation matched to the priced NDC | High |
| One-view pricing landscape | Acquisition cost, ASP, Medicare spend, transparency payments, shortages, and NDC data combined into one sourced pricing overview. | MCP | days of multi-portal CMS/FDA work → one turn | High |
| HEOR budget-impact / CEA model inputs | Supplies the utilization, unit-cost, and spend inputs your model needs — it populates the model, it doesn't run it. | MCP | faster model population (no built-in model) | Medium |
| Value dossier / AMCP evidence assembly | Pulls pricing, trials, labels, safety, and IP into sourced, attributed sections your dossier can draw on. | Both | dossier evidence pre-gathered and attributed | Medium |
Straight answers on where ClinicaLister stops today — so there are no surprises.
Purple Book / biosimilar coverage is 3.07% of drug records (915 of 29,777; only 48 carry a biosimilar mention) and exclusivity end-dates 1.8%, measured 2026-08-17. Biosimilar and interchangeability status is therefore a per-drug lookup that often comes back empty — it is not a tracked feed, and it cannot time loss-of-exclusivity.
US and Medicare-centric. All pricing is US public data — there's no ex-US or OECD reference pricing and no international HTA references.
List and acquisition anchors only, no net prices. You get acquisition cost, ASP, and list benchmarks — not commercial or PBM-negotiated prices, rebates, or actual gross-to-net.
It feeds the model, it doesn't build it. ClinicaLister supplies utilization, unit-cost, and spend inputs — but there's no budget-impact or cost-effectiveness engine, no QALYs, ICERs, or survival models.
Public CMS and FDA data only. No proprietary claims data, and no per-payer formulary, coverage-policy, or prior-authorization dataset.
Pricing lives with your AI assistant, not the app charts. The ClinicaLister app charts no pricing or reimbursement data — realising these wins runs through an AI-assistant workflow, not the app UI.
Acquisition cost, ASP, Medicare spend, transparency payments, and shortages assembled into one sourced pricing view beside the drug — the only place these public pillars come together, every figure traced to its CMS or FDA origin.